DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

AZ’s single inhaler, PT010 ... for medicines that could reduce likelihood of expensive emergency hospital visits due to COPD. Further details of the KRONOS trial will be announced at an upcoming ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Boehringer Ingelheim (BI) is to work with Qualcomm to 'digitally upgrade' its Respimat inhaler ... is a common issue in COPD patients and frequently results in emergency hospital admissions.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Additionally, a pMDI with a spacer is preferred to provide a sufficient dose in an emergency situation ... GSK, leading the COPD market with its Trelegy Ellipta inhaler, is planning pivotal ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.